Report Content

Chapter 1   Methodology

1.1    Methodology

1.2    Market definitions

1.3    Forecast parameters

1.4    Data sources

1.4.1    Secondary

1.4.1.1    Paid sources

1.4.1.2    Unpaid sources

1.4.2    Primary

Chapter 2   Executive Summary

2.1    North America cell line development market industry 360⁰ synopsis, 2016 - 2027

Chapter 3   North America Cell Line Development Market Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 - 2027

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Growing vaccine production

3.3.1.2    Increasing cancer prevalence

3.3.1.3    Growth in biotechnology industry

3.3.1.4    Innovations in biologics due to patent expirations

3.3.1.5    Rising demand for monoclonal antibodies

3.3.1.6    Technological innovation in cell line development

3.3.2    Industry pitfalls & challenges

3.3.2.1    Issues related to stem cell research

3.4    COVID-19 impact analysis

3.5    Competitive review, 2020

3.5.1    Strategy dashboard

3.6    Porter’s analysis

3.7    PEST analysis

Chapter 4   North America Cell Line Development Market, By Product

4.1    Key segment trends

4.2    Reagents and media

4.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3    Equipment

4.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.2    Incubators

4.3.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.3    Centrifuges

4.3.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.4    Bioreactors

4.3.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.5    Storage equipment

4.3.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.6    Microscopes

4.3.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4    Accessories & consumables

4.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5   North America Cell Line Development Market, By Source

5.1    Key segment trends

5.2    Mammalian

5.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3    Non-mammalian

5.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3.2    Insects

5.3.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3.3    Amphibians

5.3.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 6   North America Cell Line Development Market, By Cell Line Type

6.1    Key segment trends

6.2    Recombinant cell lines

6.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3    Hybridomas

6.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.4    Continuous cell lines

6.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.5    Primary cell lines

6.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7   North America Cell Line Development Market, By Application

7.1    Key segment trends

7.2    Bioproduction

7.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3    Drug discovery

7.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4    Toxicity testing

7.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.5    Tissue engineering

7.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.6    Research

7.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8   North America Cell Line Development Market, By Country

8.1    Key country trends

8.2    North America

8.2.1    Market estimates and forecast by country, 2016 - 2027 (USD Million)

8.2.2    Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.3    Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.4    Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.5    Market estimates and forecast by application, 2016 - 2027 (USD Million)

8.2.6    U.S.

8.2.6.1    Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.6.2    Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.6.3    Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.6.4    Market estimates and forecast by application, 2016 - 2027 (USD Million)

8.2.7    Canada

8.2.7.1    Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.7.2    Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.7.3    Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.7.4    Market estimates and forecast by application, 2016 - 2027 (USD Million)

Chapter 9   Company Profiles

9.1    GE Healthcare

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Product landscape

9.1.4    Strategic outlook

9.2    Thermo Fisher Scientific Inc.

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.3    Lonza Group AG

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.4    Sigma-Aldrich Corporation (Merck)

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.5    WuXi AppTec

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.6    Sartorius Stedim Biotech GmbH

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.7    Corning Inc.

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.8    Selexis SA

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.9    GVK BIO

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.10    Vista Biologicals

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook